Presence of central nervous system (CNS) involvement requiring active treatment
Symptomatic or progressing or steroid requiring Central Nervous System (CNS) involvement disease at least four weeks prior to randomization
Current or past history of central nervous system (CNS) disease, or CNS involvement by MM
Symptomatic central nervous system (CNS) involvement which are neurologically unstable or requiring increasing doses of steroids to control.
Central nervous system (CNS) involvement
Patients with metabolic storage diseases who have severe central nervous system (CNS) involvement of disease, defined as intelligence quotient (IQ) score < 
Subject has confirmed central nervous system (CNS) involvement by DLBCL. Subjects at risk for CNS involvement per Investigator assessment must receive prophylaxis. For subjects at risk, or with any neurological symptoms, testing for CNS involvement is required at Screening.
Has clinical signs of central nervous system (CNS) involvement of MM.
Central Nervous System (CNS) involvement with multiple myeloma defined as csf positivity for plasma cells or a parenchymal CNS plasmacytoma
Active central nervous system (CNS) involvement by malignancy, except in cases of virus-associated malignancies with CNS involvement in which case the patient may benefit from the transplant to control the malignancy
Known clinically active central nervous system (CNS) involvement; prior evidence of CNS involvement successfully treated with surgery or radiation therapy will not be exclusion for participation as long as they are deemed under control at the time of study enrollment and there are no neurological signs of potential CNS involvement
Prior central nervous system (CNS) involvement by tumor cells;
Active central nervous system (CNS) involvement by malignancy
Patients with history of central nervous system (CNS) involvement
Active central nervous system (CNS) metastases and/or leptomeningeal involvement
The toxicity profile of nivolumab in patients with disease involvement of the central nervous system (CNS) is unknown
Evidence of active central nervous system (CNS) involvement
Central nervous system (CNS) involvement, including lymphomatous meningitis
Prior central nervous system (CNS) involvement by tumor cells
No active central nervous system (CNS) metastatic disease. NOTE: Subjects with CNS involvement must meet ALL of the following to be eligible:
Active central nervous system (CNS) involvement or leptomeningeal involvement
Patients with current central nervous system (CNS) involvement by malignancy (either by imaging or cerebrospinal fluid involvement or biopsy-proven)
Active, untreated central nervous system (CNS) involvement
Active central nervous system (CNS)-only involvement by malignancy (note: participants with secondary CNS involvement are allowed on study)
Central nervous system (CNS) involvement
Uncontrolled central nervous system (CNS) involvement by tumor cells within the past  months
Central nervous system (CNS) involvement
History of or active central nervous system (CNS) or peripheral nerve stimulation (PNS) involvement
Patients with current central nervous system (CNS) involvement by malignancy (either by imaging or cerebrospinal fluid involvement or biopsy-proven)
Active central nervous system (CNS) involvement within the previous  months
Active central nervous system (CNS) involvement of the underlying malignancy
Known evidence of active cerebral/meningeal CLL; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration
Central nervous system (CNS) involvement
Active central nervous system (CNS) neoplastic involvement
Patients with central nervous system (CNS) metastases or symptomatic CNS involvement (including cranial neuropathies or mass lesions)
Patients with history of extramedullary AML, except for central nervous system (CNS) involvement that is currently controlled, will not be eligible for enrollment
Central nervous system (CNS) involvement within  months
Patient must have no current or prior history of central nervous system (CNS) involvement
Patient with active central nervous system (CNS) involvement
Patients with active central nervous system (CNS) involvement by malignant cells
Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study)
Patient has a known or suspected primary central nervous system (CNS) tumor or CNS tumor involvement or active leptomeningeal disease.
Patient has distant metastatic disease, including central nervous system (CNS) tumor involvement
Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:
Symptomatic central nervous system (CNS) involvement by AML
Untreated central nervous system (CNS) involvement
Active central nervous system (CNS) involvement or leptomeningeal metastases involvement
Uncontrolled central nervous system (CNS) disease involvement
Has known clinically active central nervous system (CNS) involvement OR history of resolved CNS involvement by multiple myeloma
Patients with history of central nervous system (CNS) involvement or active CNS involvement by malignancy
Patients with metabolic storage diseases who have severe central nervous system (CNS) involvement of disease, defined as intelligence quotient (IQ) score < 
Active central nervous system (CNS) involvement by malignancy
Active Central Nervous System (CNS) involvement by malignancy
Have active leukemic involvement of the central nervous system (CNS).
Patients who have symptomatic central nervous system (CNS) involvement are not eligible
Active central nervous system (CNS) involvement of disease
Central nervous system (CNS) involvement.
Patients with documented central nervous system (CNS) involvement
Participants with active central nervous system (CNS) involvement are excluded; patients with suspected CNS disease should be worked up appropriately prior to enrollment
Patient has active or history of central nervous system (CNS) disease or meningeal involvement
Known evidence of active cerebral/meningeal CLL; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration
Central nervous system (CNS) involvement by CLL.
Research participants with known brain metastases (central nervous system [CNS] involvement either parenchymal or leptomeningeal involvement)
Has evidence of uncontrolled central nervous system (CNS) involvement (previous radiation and off steroids is acceptable)
History of central nervous system (CNS) involvement by myeloma
Patients with central nervous system (CNS) involvement
Untreated central nervous system (CNS) involvement; (treated CNS involvement is permitted only if the patient is not currently on steroid therapy or has remained on a stable, unchanged dose of steroid for >=  weeks)
Active central nervous system or meningeal involvement by lymphoma; patients with a history of central nervous system (CNS) or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast magnetic resonance imaging (MRI) for at least  months prior to study entry
Patient with active central nervous system (CNS) involvement with lymphoid malignancy
Uncontrolled central nervous system (CNS) involvement with disease
Evidence of AML central nervous system (CNS) involvement
Central nervous system (CNS) involvement.
Active diagnosis of central nervous system (CNS) involvement with CLL
Active central nervous system (CNS) involvement by malignancy (defined as CNS- per National Comprehensive Cancer Network [NCCN] guidelines)
Patient has central nervous system metastatic involvement. Patients with previously treated CNS metastases are also excluded.
Central nervous system (CNS) involvement of DLBCL
Active central nervous system (CNS) disease involvement
Clinically active central nervous system (CNS) cancer involvement. Imaging to exclude CNS involvement not required.
Symptomatic central nervous system (CNS) involvement
Had evidence of active central nervous system (CNS) involvement
Symptomatic central nervous system (CNS) involvement
Active or symptomatic central nervous system (CNS) disease or epidural involvement
Evidence of active cerebral/meningeal disease; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration
Symptomatic, steroid-requiring or progressive central nervous system (CNS) involvement
Active involvement of the Central Nervous System (CNS).
Clinically uncontrolled central nervous system (CNS) involvement
Patients with central nervous system (CNS) metastatic involvement.
Clinically uncontrolled central nervous system (CNS) involvement
Active central nervous system (CNS) involvement of their malignancy.
Uncontrolled central nervous system (CNS) involvement by tumor cells
Active central nervous system (CNS) involvement by malignancy
Prior central nervous system (CNS) involvement by tumor is permissible if previously treated and clinically stable for two weeks after completion of treatment.
Known evidence of active cerebral/meningeal CLL; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration
History of central nervous system (CNS) involvement
Patient must not have active central nervous system (CNS) involvement
Active central nervous system (CNS) involvement by malignant cells
EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Active involvement of the central nervous system with malignancy (previous central nervous system [CNS] involvement is allowed if clearance of CNS disease has been documented prior to enrollment)
Active central nervous system (CNS) involvement by malignant cells
Active central nervous system (CNS) involvement by malignant cells
Active central nervous system (CNS) involvement by malignant cells
Clinical signs of central nervous system (CNS) involvement of MM.